Anti-HIV type 1 memory cytotoxic T lymphocyte responses associated with changes in CD4+ T cell numbers in progression of HIV type 1 infection. 1998

C R Rinaldo, and P Gupta, and X L Huang, and Z Fan, and J I Mullins, and S Gange, and H Farzadegan, and R Shankarappa, and A Muñoz, and J B Margolick
University of Pittsburgh School of Medicine, Pennsylvania 15261, USA.

We investigated memory cytotoxic T lymphocyte (CTLm) responses to HIV-1 as a determinant of HIV-1 disease progression, in relation to plasma HIV-1 load and T lymphocyte numbers in a longitudinal study of 14 homosexual men with incident HIV-1 infection. Study participants were selected who exhibited failure of T cell homeostasis, i.e., a downward inflection in CD3+ T cells that occurs in >75% of persons 1.5 to 2.5 years before development of AIDS, and compared with participants who developed low CD4+ T cell counts associated with possible T cell homeostasis failure, a subject who progressed rapidly to AIDS without well-defined T cell inflection, and subjects who had long-term preservation of T cell homeostasis (nonprogressors). High CTLm responses against Gag, but not Pol or Env, soon after seroconversion were associated with a slower loss of CD4+ T cells 1-4 years after seroconversion. Anti-Env CTLm responses decreased in most subjects around the time that T cell homeostasis failed. Plasma HIV-1 RNA increased exponentially (1.59-fold per year) over the 5 years preceding failure of T cell homeostasis, and there was a shift from a non-syncytium-inducing/CCR5 coreceptor phenotype of HIV-1 to a syncytium-inducing/CXCR4 phenotype, regardless of high or increasing levels of anti-HIV-1 CTLm during this time. These observations suggest that decreases in CTLm and increasing virus load are independent factors contributing to HIV-1 disease progression.

UI MeSH Term Description Entries
D007156 Immunologic Memory The altered state of immunologic responsiveness resulting from initial contact with antigen, which enables the individual to produce antibodies more rapidly and in greater quantity in response to secondary antigenic stimulus. Immune Memory,Immunological Memory,Memory, Immunologic,Immune Memories,Immunologic Memories,Immunological Memories,Memory, Immune,Memory, Immunological
D008137 Longitudinal Studies Studies in which variables relating to an individual or group of individuals are assessed over a period of time. Bogalusa Heart Study,California Teachers Study,Framingham Heart Study,Jackson Heart Study,Longitudinal Survey,Tuskegee Syphilis Study,Bogalusa Heart Studies,California Teachers Studies,Framingham Heart Studies,Heart Studies, Bogalusa,Heart Studies, Framingham,Heart Studies, Jackson,Heart Study, Bogalusa,Heart Study, Framingham,Heart Study, Jackson,Jackson Heart Studies,Longitudinal Study,Longitudinal Surveys,Studies, Bogalusa Heart,Studies, California Teachers,Studies, Jackson Heart,Studies, Longitudinal,Study, Bogalusa Heart,Study, California Teachers,Study, Longitudinal,Survey, Longitudinal,Surveys, Longitudinal,Syphilis Studies, Tuskegee,Syphilis Study, Tuskegee,Teachers Studies, California,Teachers Study, California,Tuskegee Syphilis Studies
D008297 Male Males
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D006706 Homeostasis The processes whereby the internal environment of an organism tends to remain balanced and stable. Autoregulation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013602 T-Lymphocytes, Cytotoxic Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2. Cell-Mediated Lympholytic Cells,Cytotoxic T Cells,Cytotoxic T Lymphocyte,Cytotoxic T-Lymphocytes,TC1 Cell,TC1 Cells,TC2 Cell,TC2 Cells,Cell Mediated Lympholytic Cells,Cell, Cell-Mediated Lympholytic,Cell, TC1,Cell, TC2,Cell-Mediated Lympholytic Cell,Cytotoxic T Cell,Cytotoxic T Lymphocytes,Cytotoxic T-Lymphocyte,Lymphocyte, Cytotoxic T,Lympholytic Cell, Cell-Mediated,Lympholytic Cells, Cell-Mediated,T Cell, Cytotoxic,T Lymphocyte, Cytotoxic,T Lymphocytes, Cytotoxic,T-Lymphocyte, Cytotoxic
D014766 Viremia The presence of viruses in the blood. Viremias
D015496 CD4-Positive T-Lymphocytes A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes. T4 Cells,T4 Lymphocytes,CD4-Positive Lymphocytes,CD4 Positive T Lymphocytes,CD4-Positive Lymphocyte,CD4-Positive T-Lymphocyte,Lymphocyte, CD4-Positive,Lymphocytes, CD4-Positive,T-Lymphocyte, CD4-Positive,T-Lymphocytes, CD4-Positive,T4 Cell,T4 Lymphocyte
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human

Related Publications

C R Rinaldo, and P Gupta, and X L Huang, and Z Fan, and J I Mullins, and S Gange, and H Farzadegan, and R Shankarappa, and A Muñoz, and J B Margolick
August 2001, AIDS research and human retroviruses,
C R Rinaldo, and P Gupta, and X L Huang, and Z Fan, and J I Mullins, and S Gange, and H Farzadegan, and R Shankarappa, and A Muñoz, and J B Margolick
August 1993, AIDS (London, England),
C R Rinaldo, and P Gupta, and X L Huang, and Z Fan, and J I Mullins, and S Gange, and H Farzadegan, and R Shankarappa, and A Muñoz, and J B Margolick
June 1994, Journal of acquired immune deficiency syndromes,
C R Rinaldo, and P Gupta, and X L Huang, and Z Fan, and J I Mullins, and S Gange, and H Farzadegan, and R Shankarappa, and A Muñoz, and J B Margolick
February 1998, The New England journal of medicine,
C R Rinaldo, and P Gupta, and X L Huang, and Z Fan, and J I Mullins, and S Gange, and H Farzadegan, and R Shankarappa, and A Muñoz, and J B Margolick
October 2011, The Journal of allergy and clinical immunology,
C R Rinaldo, and P Gupta, and X L Huang, and Z Fan, and J I Mullins, and S Gange, and H Farzadegan, and R Shankarappa, and A Muñoz, and J B Margolick
August 2007, Vaccine,
C R Rinaldo, and P Gupta, and X L Huang, and Z Fan, and J I Mullins, and S Gange, and H Farzadegan, and R Shankarappa, and A Muñoz, and J B Margolick
April 2000, AIDS research and human retroviruses,
C R Rinaldo, and P Gupta, and X L Huang, and Z Fan, and J I Mullins, and S Gange, and H Farzadegan, and R Shankarappa, and A Muñoz, and J B Margolick
December 2000, AIDS research and human retroviruses,
C R Rinaldo, and P Gupta, and X L Huang, and Z Fan, and J I Mullins, and S Gange, and H Farzadegan, and R Shankarappa, and A Muñoz, and J B Margolick
August 2006, AIDS research and human retroviruses,
C R Rinaldo, and P Gupta, and X L Huang, and Z Fan, and J I Mullins, and S Gange, and H Farzadegan, and R Shankarappa, and A Muñoz, and J B Margolick
December 2021, Cold Spring Harbor perspectives in biology,
Copied contents to your clipboard!